Research and Development

Every year Omikron Italia invests about 15% of its turnover in Research and Development on projects carried out in collaboration with the most prestigious Italian and foreign Institutes.

The Main Fields of Research are the following:

  • Vasal Contractility and Permeability
  • Preclinical development of a new flavonoid
  • Hemorrhoidal disease
  • Retina
  • Glaucoma
Discover more

Main Fields of Research

Vasal Contractility and Permeability

A multi-year framework agreement with a US University Institute is in place.

Preclinical development of a new flavonoid
 Hemorrhoidal disease
  • A multicenter, prospective, randomized, controlled, triple-blind Clinical study, performed indipendently by the Italian Society of Colo-Rectal Surgery (SICCR) to evaluate the effectiveness of our mixture of flavonoids in the treatment of acute hemorrhoidal disease, has ended and was published in an International Journal.
  • The preclinical and clinical development of a new formulation for topical use in the treatment of hemorrhoids has just ended.
Retina
  • An Experimental Trial on the treatment of Diabetic Retinopathy performed by an Italian University Institute has ended and was published in an International Journal.
  • An Experimental Trial performed by the National Health Institute (Istituto Superiore di Sanità) in vitro on retina cell cultures and in vivo with rats in order to assess the neuro-protective effect on structural and functional possible alteration on the retinal neuroglia component in the diabetic disease has ended and was published in an International Journal.
  • A Clinical Trial on the Treatment of Diabetic Retinopathy performed by an Italian Research Institute has ended and was published in an International Journal.
  • A Clinical Trial on corneal morphology and functionality performed by an Italian University Institute in patients with Diabetic Retinopaty has ended and was published in an International Journal.
Glaucoma
  • The first multicenter Experimentation with citicoline in oral solution, never carried out before on the progression of the campimetric damage in glaucomatous patients has been performed and was published in an International Journal.
  • The preclinical and clinical development of OMK1®, citicoline and hyaluronic acid in ophthalmic solution (Medical Device CE) and of OMK2®, citicoline, hyaluronic acid and vitamine B12 in ophthalmic solution (Medical Device CE) has been carried out in Italy.
  • A Clinical Trial performed by an Italian Research Institute with citicoline in ophthalmic solution in the treatment of glaucomatous patients has ended and was published in an International Journal.
  • A Clinical Trial performed by an Italian Institute on the treatment of patients with neurodegenerative diseases involving the optic nerve has ended and was published in an International Journal.
  • A multicenter Randomized Clinical Trial (RCT) with citicoline in ophthalmic solution in glaucomatous patients with progression damage has ended and was published in an International Journal; this Trial has been performed by Italian University Institutes and provided morphological and functional evaluations.
  • An ocular kinetics study in human performed with citicoline in ophthalmic solution in patients undergoing vitrectomy has ended and was published in an International Journal.
  • The preclinical and clinical development of a new formulation for ophthalmic use in the treatment of glaucoma has just ended; first experimental and clinical studies with this new formulation have been already published in an International Journal.
THERAPEUTIC AREA PHARMACEUTICAL FORM EXPECTED LAUNCH
Ophthalmology/Glaucoma eye-drops 2024
Ophthalmology/FANS eye-drops in gel 2025
Vascular disease (Antithrombotic) solution for injection 2023 (IV)
Patent Application: PCT/IB2011/050663
Title document: TOPICAL CITICOLINE FOR THE TREATMENT OF GLAUCOMA
APPLICATION NUMBER PUBLICATION STATUS TITLE DOCUMENT HOLDER (PATENT HOLDER)
PCT WO2011101802 25/08/2011 OMIKRON ITALIA
NATIONAL STAGE EUROPE
EP2538918
02/01/2013 GRANT OF PATENT IS INTENDED
06/06/2014
OMIKRON ITALIA
NATIONAL STAGE USA
US8822429
13/12/2012 GRANT OF PATENT IS INTENDED
13/08/2014
OMIKRON ITALIA
NATIONAL STAGE JAPAN
JP5801324
04/09/2015 GRANT OF PATENT IS INTENDED
18/08/2015
OMIKRON ITALIA
Patent Application: PCT/IB2017/056400
Title document: OPHTHALMIC FORMULATION COMPRISING CITICOLINE CARRIED BY LIPOSOME FOR THE TREATMENT OF GLAUCOMA
APPLICATION NUMBER PUBLICATION STATUS TITLE DOCUMENT HOLDER
(PATENT HOLDER)
PCT WO2018073720 26/04/2018
NATIONAL STAGE USA
US 10576039
16/04/2019 GRANT OF PATENT IS INTENDED
03/03/2020
OMIKRON ITALIA
ABIOGEN PHARMA
Pisa – Italy
Glibenclamide + Meformin Hydrocloride (Diaglimet ®)
RRR-α-tochoperol (Armilla ®)
URSAPHARM Arzneimittel GmbH
Germany
Retinol Palmitate (VitA-POS)

Thanks to licensing agreements with foreign major pharmaceutical companies, since 2013 Omikron Italia started an important internationalization process that is more and more consolidating and increasing over the years.

Some Omikron Italia medicinal products, medical devices and nutraceuticals are already marketed in several European Countries and Extra European Countries. Moreover, registrations in 3 different continents are currently ongoing.

The continuous innovation of proposed therapeutic approaches together with an increasing attention to the quality of the products, to the interest towards the therapeutic needs of patients and to the constant efforts in Research allowed Omikron Italia to steadily expand over the years in many Countries.

Partnership Map

Partnership Map

Countries with direct presence

Countries with indirect presence (marketing of Omikron Italia products through business partner)

Countries with indirect presence (marketing agreements about Omikron Italia products with registration process ongoing)

Research Award A.I.S.G. – Omikron Italia 2023 “Marco Centofanti” su: Neuroprotezione e Glaucoma

Omikron Italia, a leading company in the ophthalmic sector, intends to actively contribute to the development of research in Italy through funding for 2 young researchers active in the physiopathological and / or clinical field relating to Neuroprotection in Glaucoma.

Read and download the complete announcement, fill in the fields indicated and send your Curriculum Vitae together with the full text of the publications of Research Projects previously conducted in the aforementioned area to the e-mail addresses dir.amministrativa@omikronitalia.it and oftalmologicaaisg@libero.it by December 31, 2022.

Get involved